IGF::OT::IGF SBIR TOPIC 347 PHASE I

癌症是美国第二大常见的死亡原因，然而，通过早期发现，死亡率通常会大大降低。 早期检测癌症的一种有前途的方法是鉴定肿瘤生物标志物。 组织中生物标志物的鉴定可能比循环生物标志物更有价值，因为它们伴随着空间信息，以及评估细胞类型和标志物相互作用的可能性。 目前，在临床上最常用的方法是在福尔马林固定、石蜡包埋的组织切片中原位检测生物标志物。 然而，生物标志物定位的分辨率有限，限制了定量分析。 免疫荧光法已广泛应用于标本的自体荧光检测和低限检测。 Luna提出开发用于肿瘤生物标志物鉴定和定量的等离子体金属纳米颗粒增强的荧光免疫测定试剂盒。 NIR染料荧光被金属纳米颗粒增强到超过5000倍，从而将载玻片测定灵敏度和LOD高度增加到阿摩尔范围。 Luna的试剂盒保存起来非常稳定，使用非常简单，不会改变当前的检测格式和程序。

Cancer is the second most common cause of death in the United States, however, the mortality rate is often greatly reduced by early detection. One promising approach in the early detection of cancer is to identify tumor biomarkers. Identification of biomarkers in tissues can have more value than circulating biomarkers as they are accompanied by spatial information, and the possibility to assess the interaction of cell types and markers. Currently, measuring biomarkers in-situ in formalin-fixed, paraffin-embedded tissue sections by immonohistochemistry is the most common method in clinic. However, the resolution of biomarker localization is limited which restricts quantitative analysis. Immunofluorescence has been widely used in autoflurenscence of specimen and the low limit. luna proposes to develop a plasmonic metal nanoparticle enhanced fluorescense immunoassay kit for tumor biomarker identification and quantificcation. The NIR dye fluorescence is enhanced by metal noanoparticles to more than 5000 fold and thus highly increase the slide assay sensitivity and LOD to the attomolar range. Luna's kit is highly stable to keep and very simple to use and does not alter the current assay format and procedures.